Alternating Current Stimulation for Optic Neuropathy
Trial Summary
Do I need to stop my current medications for the trial?
The trial protocol does not specify whether you need to stop taking your current medications. However, certain medical conditions and treatments, like epilepsy on medical treatment or uncontrolled diabetes, may affect eligibility.
What data supports the effectiveness of the treatment SAVIR Alpha Synch mobile (SASm) for optic neuropathy?
Research shows that alternating current stimulation (ACS) can improve vision in patients with optic nerve damage by enhancing brain activity and promoting recovery of visual functions. Studies suggest that this non-invasive treatment helps the brain's natural ability to adapt and recover, offering a promising option for those with optic neuropathy.12345
Is alternating current stimulation safe for humans?
How is the treatment SAVIR Alpha Synch mobile (SASm) different from other treatments for optic neuropathy?
The SAVIR Alpha Synch mobile (SASm) treatment uses non-invasive alternating current stimulation (ACS) to help improve vision in patients with optic neuropathy by leveraging the brain's ability to adapt and recover visual functions. This approach is unique because it stimulates the visual system without surgery or medication, aiming to restore vision by enhancing the brain's plasticity.23459
What is the purpose of this trial?
The purpose of this study is to test the efficacy and feasibility of an intervention protocol for home-based repetitive transorbital alternating current stimulation (rtACS) for the treatment of visual impairment in people with optic neuropathy. The primary aims are to evaluate the effectiveness of home-based rtACS to ameliorate the progressive effects of vision loss functionally in the eye and the visual pathway, and in regard to people's independence (i.e., functional ability).
Research Team
Joseph Panarelli, MD
Principal Investigator
NYU Langone Health
Eligibility Criteria
This trial is for individuals with optic neuropathy, a condition affecting the eye nerves. Participants should be willing to undergo home-based treatment involving repetitive electrical stimulation (rtACS) aimed at improving vision and independence.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo 30 stimulation sessions of home-based repetitive transorbital alternating current stimulation (rtACS), with the first two sessions in-office and the remaining 28 at-home over 8 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- SAVIR Alpha Synch mobile (SASm)
Find a Clinic Near You
Who Is Running the Clinical Trial?
NYU Langone Health
Lead Sponsor